IP Library Granted Patent US 10,208,017
Granted Patent B2
US 10,208,017 · App. 14/404,839 · Granted Feb 19, 2019

Heterocycles capable of modulating T-cell responses, and methods of using same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,208,017
App. No.
14/404,839
Granted
Feb 19, 2019
Kind
B2
Abstract

The present disclosure is directed in part to heterocycles, and their use in treating medical disorders, such as immune inflammatory disorders such as Crohn's disease, ulcerative colitis, rheumatic disorders, psoriasis, and allergies. The compounds are contemplated to modulate T-Cell responses.

Claims (15)

1. A method of treating an immune inflammatory disease or disorder in a subject in need thereof, the method comprising administering to the subject a pharmaceutically effective amount of a compound having the formula:

or a pharmaceutically acceptable salt thereof,

wherein the immune inflammatory disease or disorder is selected from the group consisting of Crohn's disease, ulcerative colitis, a rheumatic disorder, psoriasis, and an allergy.

2. The method of claim 1 , wherein the allergy is contact dermatitis or atopic dermatitis.

3. A pharmaceutical composition comprising:

a heterocyclic compound having the formula:

or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable adjuvant or excipient, wherein the heterocyclic compound is present in a therapeutically effective amount in the pharmaceutical composition.

4. The method of claim 2 , wherein the allergy is contact dermatitis.

5. The method of claim 2 , wherein the allergy is atopic dermatitis.

6. The method of claim 1 , wherein the immune inflammatory disease or disorder is Crohn's disease.

7. The method of claim 1 , wherein the immune inflammatory disease or disorder is ulcerative colitis.

8. The method of claim 1 , wherein the immune inflammatory disease or disorder is a rheumatic disorder.

9. The method of claim 1 , wherein the immune inflammatory disease or disorder is psoriasis.

10. The method of claim 1 , wherein the immune inflammatory disease or disorder is an allergy.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2015
From: VAN DEN BRINK, GIJS; VERHAAR, AUKE; HOMMES, DAAN; VITI, FRANCESCA
To: NOGRA PHARMA LIMITED
Reel/Frame 035082/0150 →